Published by Josh White on 23rd March 2026
(Sharecast News) - TheraCryf said on Monday that its lead Ox-1 receptor antagonist programme for addiction had advanced to final toxicology studies, keeping the biotech group on track to begin human clinical trials by the end of 2026.
URL: http://www.digitallook.com/dl/news/story/35804693/...